Results 121 to 130 of about 3,641 (145)

US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018

Clinical Trials, 2021
Audrey Zhang, Joshua D Wallach, Joshua Skydel   +2 more
exaly  

PostMarket Surveillance of Medical Products in the United States

2010
Paul J. Seligman, Thomas P. Gross, M. Miles Braun, Janet B. Arrowsmith   +3 more
openaire   +1 more source

Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999–2002

Current Medical Research and Opinion, 2009
William T Barry, Frank G Bottone
exaly  

Informatic Tools and Approaches in Postmarketing Pharmacovigilance Used by FDA

AAPS Journal, 2008
Mark I Avigan
exaly  

FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients

Research in Social and Administrative Pharmacy, 2020
Daniel Dauner, Kim Nichols Dauner
exaly  

Characteristics and follow‐up of postmarketing studies of conditionally authorized medicines in the EU

British Journal of Clinical Pharmacology, 2016
Marie Louise De Bruin, Jarno Hoekman
exaly  

Postmarketing surveillance for drug abuse

Drug and Alcohol Dependence, 2003
Theodore Cicero, Cynthia Arfken
exaly  

Rivaroxaban postmarketing risk of liver injury

Journal of Hepatology, 2014
Gerd A Kullak-Ublick, Bruno Stieger, Stefan Russmann   +2 more
exaly  

Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation

Chinese Journal of Integrative Medicine, 2014
Xing Liao, Yan-Ming Xie, Xie Yan-Ming
exaly  

Famotidine: Postmarketing Clinical Experience

Scandinavian Journal of Gastroenterology, 1987
K Saigenji
exaly